Vol 2, No 1 (2011)
Review paper
Published online: 2011-03-24

open access

Page views 915
Article views/downloads 3550
Get Citation

Connect on Social Media

Connect on Social Media

Deferasirox (Exjade®) as iron chelator in children

Michał Matysiak
Hematologia 2011;2(1):83-87.

Abstract

Patients receiving recurrent blood transfusion as supportive therapy of chronic anemia in the course of myelodysplastic syndromes, thalassemia and sickle-cell disease, are at risk of iron accumulation. The clinical consequences of iron overload can be fatal. Therefore, the use of a chelating agent is required to promote excretion of iron. At the present time, new iron chelators that can be given orally are available. Deferasirox is a once-daily oral therapy for treating transfusional iron overload, which improves patient compliance and quality of his life.
Hematologia 2011; 2, 1: 83–87

Article available in PDF format

View PDF (Polish) Download PDF file



Hematology in Clinical Practice